The study identifies a potential drug target to treat diabetes.
Researchers reversed insulin resistance and glucose intolerance in mice when they removed a key protein, suggesting it could be a target for drugs that would correct diabetes.
The team from the University of California at San Diego (UCSD) studied the effects of galectin-3, or Gal3, which prevents insulin from attaching to receptors, causing insulin resistance.
The researchers, led by senior author Jerrold Olefsky, MD, showed that when Gal3 was genetically removed or chemically blocked, the mice regained insulin sensitivity and glucose tolerance. Obesity, however, was unchanged.
“This study puts Gal3 on the amp for insulin resistance and diabetes in the mouse model,” said Olefsky, professor of medicine in the Division of Endocrinology and Metabolism and associate dean for Scientific Affairs at UCSD, in a statement. “Our findings suggest that Gal3 inhibition in people could be an effective antidiabetic approach.”
The findings appeared in the new issue of Cell.
Olefsky and his team have been studying the process of inflammation, which triggers insulin resistance in type 2 diabetes—the most common form of the disease, affecting more than 27 million people in the United States.
The paper in Cell explains the role of special cells called macrophages in inflammation; these cells secrete Gal3 in a snowball effect—the more Gal3, the more the protein attracts macrophages, which, in turn, secrete more of the protein. Researchers identify bone marrow as the original source of the macrophages, but note that they accumulate in fat tissue, which would explain why obesity is linked with type 2 diabetes.
Inhibition of the protein, by contrast, could treat insulin resistance and diabetes. The researchers note that Gal3 has been implicated in other diseases liked to inflammation.
Reference
Pingping L, Liu S, Lu M, et al. Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell. 2016;167(4):973. doi: 10.1016/j.cell.2016.10.025.
Exclusive Telemedicine Use Linked to Less Favorable Glycemic Outcomes for T2D Endocrinology Care
December 6th 2023Adults with type 2 diabetes (T2D) undergoing endocrinology care are more likely to experience less favorable hemoglobin A1c improvements if they only use telemedicine compared with patients using in-person care or a mix of both.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Study Reveals Factors That Further Increase Colorectal Cancer Risk for Adults With T2D
November 14th 2023The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.
Read More
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen